Flunisolide hydrofluoroalkane inhalation - Allergan

Drug Profile

Flunisolide hydrofluoroalkane inhalation - Allergan

Alternative Names: Aerospan; Flunisolide hemihydrate; Flunisolide HFA

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Forest Laboratories
  • Developer Allergan
  • Class Antiallergics; Antiasthmatics; Pregnadienes; Small molecules
  • Mechanism of Action Glucocorticoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Asthma

Most Recent Events

  • 05 Aug 2016 Meda has been acquired by Mylan
  • 18 Mar 2016 Efficacy data from a phase III trial in Asthma presented at the 2016 Annual Meeting of the American Academy of Allergy, Asthma and Immunology (AAAAI-2016)
  • 22 Sep 2014 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top